Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Aveo gets $61mm through private placement

04 Nov 2010

Executive Summary

Aveo Pharmaceuticals Inc. (cancer) grossed $61mm through the private placement of 4.5mm common shares at $13.50 each (an 11% discount). Proceeds will be used for Phase III trials of the company's lead kidney cancer candidate tivozanib and Phase II trials of AV299, an anticancer antibody. JP Morgan Securities, Canaccord Genuity, and RBC Capital were the placement agents.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By